Figure 4.

PASI100. The results for the NMA on PASI100 at week 16: (A) b/tsDMARD-naïve patients including forest plot and SUCRA values. FE baseline–adjusted model DIC = 150.27. (B) TNFi-experienced patients including forest plot and SUCRA values. RE-unadjusted model DIC = 81.76. ^aWeek 24 data were used as week 16 data was not available. ^*The 95% CrI does not include 1; bimekizumab 160 mg 4W is considered better. ADA: adalimumab; b/tsDMARD-naïve: biologic and targeted synthetic DMARD-naïve; BKZ, bimekizumab; CrI, credible interval; CZP, certolizumab pegol; DIC, deviance information criterion; FE, fixed effects; GOL, golimumab; GUS, guselkumab; IXE, ixekizumab; NMA, network meta-analysis; PASI, Psoriasis Area and Severity Index; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 weeks; RE, random effects; SEC, secukinumab; SUCRA, surface under the cumulative ranking curve; TNFi-experienced, TNF inhibitor–experienced; UPA, upadacitinib